Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: lapatinib
Sponsor: GlaxoSmithKline